TY - JOUR
T1 - High-Mobility Group Box-1-Induced Angiogenesis After Indirect Bypass Surgery in a Chronic Cerebral Hypoperfusion Model
AU - Nishihiro, Shingo
AU - Hishikawa, Tomohito
AU - Hiramatsu, Masafumi
AU - Kidani, Naoya
AU - Takahashi, Yu
AU - Murai, Satoshi
AU - Sugiu, Kenji
AU - Higaki, Yusuke
AU - Yasuhara, Takao
AU - Borlongan, Cesario V.
AU - Date, Isao
N1 - Funding Information:
This work was supported by JSPS KAKENHI Grant Number JP18K16585. We thank Dr. Y. Higaki for collecting the SPECT images, and Ms. M Arao and Ms. Y Ukai for their technical assistance.
Publisher Copyright:
© 2019, The Author(s).
PY - 2019/12/1
Y1 - 2019/12/1
N2 - High-mobility group box-1 (HMGB1) is a nuclear protein that promotes inflammation during the acute phase post-stroke, and enhances angiogenesis during the delayed phase. Here, we evaluated whether indirect revascularization surgery with HMGB1 accelerates brain angiogenesis in a chronic cerebral hypoperfusion model. Seven days after hypoperfusion induction, encephalo-myo-synangiosis (EMS) was performed with or without HMGB1 treatment into the temporal muscle. We detected significant increments in cortical vasculature (p < 0.01), vascular endothelial growth factor (VEGF) expression in the temporal muscle (p < 0.05), and ratio of radiation intensity on the operated side compared with the non-operated side after EMS in the HMGB1-treated group than in the control group (p < 0.01). Altogether, HMGB1 with EMS in a chronic hypoperfusion model promoted brain angiogenesis in a VEGF-dependent manner, resulting in cerebral blood flow improvement. This treatment may be an effective therapy for patients with moyamoya disease.
AB - High-mobility group box-1 (HMGB1) is a nuclear protein that promotes inflammation during the acute phase post-stroke, and enhances angiogenesis during the delayed phase. Here, we evaluated whether indirect revascularization surgery with HMGB1 accelerates brain angiogenesis in a chronic cerebral hypoperfusion model. Seven days after hypoperfusion induction, encephalo-myo-synangiosis (EMS) was performed with or without HMGB1 treatment into the temporal muscle. We detected significant increments in cortical vasculature (p < 0.01), vascular endothelial growth factor (VEGF) expression in the temporal muscle (p < 0.05), and ratio of radiation intensity on the operated side compared with the non-operated side after EMS in the HMGB1-treated group than in the control group (p < 0.01). Altogether, HMGB1 with EMS in a chronic hypoperfusion model promoted brain angiogenesis in a VEGF-dependent manner, resulting in cerebral blood flow improvement. This treatment may be an effective therapy for patients with moyamoya disease.
KW - Cerebral hypoperfusion
KW - Encephalo-myo-synangiosis
KW - High-mobility group box-1
KW - Moyamoya disease
KW - Vascular endothelial growth factor
UR - http://www.scopus.com/inward/record.url?scp=85066901202&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066901202&partnerID=8YFLogxK
U2 - 10.1007/s12017-019-08541-x
DO - 10.1007/s12017-019-08541-x
M3 - Article
C2 - 31123914
AN - SCOPUS:85066901202
SN - 1535-1084
VL - 21
SP - 391
EP - 400
JO - NeuroMolecular Medicine
JF - NeuroMolecular Medicine
IS - 4
ER -